The Global Antimicrobial Resistance Surveillance System (GLASS) has been developed to assess the global prevalence of antimicrobial resistance and follow its development and trends.
Global AMR surveillance is a key priority of the WHO Global Action Plan against AMR (GAP), adopted by the Member States through the resolution 68.7 at the World Health Assembly of 2015 and reaffirmed in the political declaration of the 2016 high-level meeting of the United Nations General Assembly on AMR.
Member States consultations
In preparation of the GAP, WHO arranged a number of technical consultations to lay the foundation for a global surveillance programme. Sweden hosted a Member States consultation in 2014, with the purpose of raising awareness and commitment to support the development and implementation of coordinated global surveillance of AMR. The meeting included delegates from 30 countries, representing different economic settings in all six WHO regions, as well as representatives from international organisations and the Swedish Government and governmental agencies. Unanimous commitment was expressed during the meeting to prioritize the establishment of a global AMR surveillance system. This included collaboration around the development of necessary core capacities and infrastructure for national AMR surveillance and data sharing.
Key GLASS policy documents
Following the request from the Member States, WHO launched the Global Antimicrobial Resistance Surveillance System (GLASS) in March 2016. To support enrolment in the system, documents and tools were developed for operation, planning, implementation, monitoring and evaluation. During the early implementation phase (2015–2019), yearly targets on enrolment and rate of progress will be pursued, along with evaluation of the system itself. The long-term aim of GLASS is for all 194 WHO Member States to enrol and participate.
Data for global, national and local actions
Global AMR surveillance is a corner stone in the work to contain further spread of resistant organisms, as well as in appreciating the complex global and multi-sectorial aspects of the problem. The first WHO global report on AMR from 2014 showed significant gaps in the data on the global prevalence of AMR. It also emphasized the need to strengthen national AMR surveillance and to harmonize surveillance internationally.
GLASS builds on national AMR surveillance systems compiling local surveillance data, which are crucial to inform treatment guidelines and to assess the impact of interventions. GLASS promotes global surveillance standards and priorities, which may form the basis of national surveillance systems, within the context of Member States' priorities and resources.
Since the focus is on fostering and strengthening national surveillance systems, countries may enrol irrespective of the current level of national surveillance. The Collaborating Centre for AMR Containment supports WHO in the implementation process, including promoting data standard harmonization and quality assurance of reported data. Find out more about the role of the Collaborating Centre in implementing GLASS under activities. More information about GLASS and how to enrol is available on the WHO website.